ERBB2 and breast carcinoma: A Phase 1 study (NCT01394016) initially demonstrated early evidence of the clinical activity and tolerability of abemaciclib in a heavily pretreated population with refractory HR+, HER2- advanced breast cancer, either as monotherapy or in combination with fulvestrant (6).